ATE523497T1 - Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen - Google Patents

Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen

Info

Publication number
ATE523497T1
ATE523497T1 AT07847181T AT07847181T ATE523497T1 AT E523497 T1 ATE523497 T1 AT E523497T1 AT 07847181 T AT07847181 T AT 07847181T AT 07847181 T AT07847181 T AT 07847181T AT E523497 T1 ATE523497 T1 AT E523497T1
Authority
AT
Austria
Prior art keywords
diabetes
treatment
obesitas
hydroxyphenyl
new
Prior art date
Application number
AT07847181T
Other languages
English (en)
Inventor
Preben Houlberg Olesen
Anders Klarskov Petersen
Flemming Elmelund Nielsen
Lise Brown Christiansen
Holger Claus Hansen
Original Assignee
High Point Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE523497T1 publication Critical patent/ATE523497T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AT07847181T 2006-11-15 2007-11-15 Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen ATE523497T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200601486 2006-11-15
PCT/EP2007/062409 WO2008059026A1 (en) 2006-11-15 2007-11-15 Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes

Publications (1)

Publication Number Publication Date
ATE523497T1 true ATE523497T1 (de) 2011-09-15

Family

ID=39052661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07847181T ATE523497T1 (de) 2006-11-15 2007-11-15 Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen

Country Status (5)

Country Link
US (1) US7915299B2 (de)
EP (1) EP2097388B1 (de)
AT (1) ATE523497T1 (de)
CA (1) CA2669884A1 (de)
WO (1) WO2008059026A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529405T1 (de) 2006-03-31 2011-11-15 Novartis Ag (4-(4-ä6-(trifluoromethyl-pyridin-3-ylamino)-n- enthaltend-heteroarylü-phenyl)-cyclohexyl)- essigsäure-derivate und ihre pharmazeutische anwendungen
EP2097380A1 (de) 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC Neue zur behandlung von obesitas und diabetes geeignete halogenalkylsulfonsubstituierte verbindungen
WO2008059025A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
CA2669867A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
CN102617478B (zh) * 2011-01-31 2015-07-15 华东理工大学 苯并咪唑、噁唑和噻唑衍生物的合成及其应用
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
EA201492223A1 (ru) 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг Новые диазаспироциклоалканы и азаспироциклоалканы
CN104684915B (zh) 2012-09-25 2017-10-31 霍夫曼-拉罗奇有限公司 新型双环衍生物
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20150039551A (ko) * 2013-10-02 2015-04-10 제이에스알 가부시끼가이샤 경화성 조성물, 경화막 및 그의 형성 방법, 그리고 화합물
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
DK3122750T3 (da) 2014-03-26 2019-11-04 Hoffmann La Roche Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
CN107922412B (zh) 2015-09-24 2021-02-23 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
BR112019013371A2 (pt) 2017-01-06 2019-12-10 Rivus Pharmaceuticals Inc novos derivados de fenila
WO2018167001A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN112805000A (zh) 2018-08-06 2021-05-14 小利兰·斯坦福大学董事会 作为ppargc1a激活剂用于治疗神经退行性疾病的2-芳基苯并咪唑

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251837A (en) * 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3269955A (en) * 1963-05-10 1966-08-30 American Cyanamid Co Method for emitting fluorescent light using fluorescent quinazolones
US3526627A (en) * 1969-06-05 1970-09-01 American Cyanamid Co Method for preparation of quinazolones
JPS6025984A (ja) 1983-07-22 1985-02-08 Tokyo Inst Of Technol ベンゾチアジアジン誘導体の製造方法
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
WO1997009040A1 (en) 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
AU4345297A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
JP2001518069A (ja) 1997-05-02 2001-10-09 ドクター・レディーズ・リサーチ・ファウンデーション 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU6966498A (en) 1997-12-02 1998-10-30 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
JP2002527520A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
JP2002527501A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び利用
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
WO2000023416A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123279A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Verbindungen, ihre herstellung und verwendung
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
CA2370401A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
AU3957900A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
JP2002542218A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造および使用
WO2000063209A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
JP2004067629A (ja) * 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
ATE468114T1 (de) * 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
KR100791252B1 (ko) * 2003-01-23 2008-01-03 크리스탈지노믹스(주) 글리코겐 합성효소 키나아제 3β 활성 억제제, 이의제조방법 및 이를 유효성분으로 함유하는 약학 조성물
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
WO2005051984A2 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. Methods for producing olfactory gpcrs
RU2006116421A (ru) 2003-11-25 2008-01-10 Ново Нордиск А/С (DK) Анилиды салициловой кислоты
EP1758856A2 (de) * 2004-05-04 2007-03-07 Novo Nordisk A/S Indolderivate zur behandlung von obesitas
EP1836183A2 (de) * 2004-12-13 2007-09-26 Galileo Pharmaceuticals, Inc. Spiroderivate als lipoxigenaseinhibitoren
US7705157B2 (en) * 2004-12-16 2010-04-27 Symyx Solutions, Inc. Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
EP2097380A1 (de) 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC Neue zur behandlung von obesitas und diabetes geeignete halogenalkylsulfonsubstituierte verbindungen
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
CA2669867A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes

Also Published As

Publication number Publication date
CA2669884A1 (en) 2008-05-22
US20100063122A1 (en) 2010-03-11
WO2008059026A1 (en) 2008-05-22
EP2097388A1 (de) 2009-09-09
US7915299B2 (en) 2011-03-29
EP2097388B1 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
ATE523497T1 (de) Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
ATE537170T1 (de) Cgrp-rezeptorantagonisten
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
MA32811B1 (fr) Nouveaux composés
NO20072435L (no) CGRP-reseptorantagonister
EA201001639A1 (ru) Композиции и способы их получения и применения
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
ATE537168T1 (de) Substituierte oxazolidinone und ihre verwendung
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
EA201100007A1 (ru) Производные хиноксалиндиона
EA200970946A1 (ru) Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха
EA201070423A1 (ru) Диарильные соединения оксадиазолов
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
TN2011000627A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2009003981A (es) Agentes moduladores del receptor de calcio.
DE602007002792D1 (de) Verbindungen und zusammensetzungen als ppar-modulatoren
NO20055741D0 (no) Nye kjemiske forbindelser
MA32505B1 (fr) 5-alcynyl-pyrimidines
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties